JP7368867B2 - 対称性ジメチル化アルギニン分析物に対する抗体及びその用途 - Google Patents

対称性ジメチル化アルギニン分析物に対する抗体及びその用途 Download PDF

Info

Publication number
JP7368867B2
JP7368867B2 JP2021560488A JP2021560488A JP7368867B2 JP 7368867 B2 JP7368867 B2 JP 7368867B2 JP 2021560488 A JP2021560488 A JP 2021560488A JP 2021560488 A JP2021560488 A JP 2021560488A JP 7368867 B2 JP7368867 B2 JP 7368867B2
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
antibody
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021560488A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022528465A (ja
JP2022528465A5 (enExample
Inventor
ヴァルデス，ジョニー
ムン，ビョンスク
チュン，キ
チェン，ユンフェイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ARK Diagnostics Inc
Original Assignee
ARK Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ARK Diagnostics Inc filed Critical ARK Diagnostics Inc
Publication of JP2022528465A publication Critical patent/JP2022528465A/ja
Publication of JP2022528465A5 publication Critical patent/JP2022528465A5/ja
Priority to JP2023004348A priority Critical patent/JP2023056523A/ja
Application granted granted Critical
Publication of JP7368867B2 publication Critical patent/JP7368867B2/ja
Priority to JP2024212048A priority patent/JP2025032213A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01049—Glucose-6-phosphate dehydrogenase (1.1.1.49)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021560488A 2019-04-03 2019-10-07 対称性ジメチル化アルギニン分析物に対する抗体及びその用途 Active JP7368867B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023004348A JP2023056523A (ja) 2019-04-03 2023-01-16 対称性ジメチル化アルギニン分析物に対する抗体及びその用途
JP2024212048A JP2025032213A (ja) 2019-04-03 2024-12-05 対称性ジメチル化アルギニン分析物に対する抗体及びその用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962828769P 2019-04-03 2019-04-03
US62/828,769 2019-04-03
PCT/US2019/055027 WO2020204994A1 (en) 2019-04-03 2019-10-07 Antibodies to symmetrically dimethylated arginine analytes and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023004348A Division JP2023056523A (ja) 2019-04-03 2023-01-16 対称性ジメチル化アルギニン分析物に対する抗体及びその用途

Publications (3)

Publication Number Publication Date
JP2022528465A JP2022528465A (ja) 2022-06-10
JP2022528465A5 JP2022528465A5 (enExample) 2023-01-06
JP7368867B2 true JP7368867B2 (ja) 2023-10-25

Family

ID=71611808

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021560488A Active JP7368867B2 (ja) 2019-04-03 2019-10-07 対称性ジメチル化アルギニン分析物に対する抗体及びその用途
JP2023004348A Pending JP2023056523A (ja) 2019-04-03 2023-01-16 対称性ジメチル化アルギニン分析物に対する抗体及びその用途
JP2024212048A Pending JP2025032213A (ja) 2019-04-03 2024-12-05 対称性ジメチル化アルギニン分析物に対する抗体及びその用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023004348A Pending JP2023056523A (ja) 2019-04-03 2023-01-16 対称性ジメチル化アルギニン分析物に対する抗体及びその用途
JP2024212048A Pending JP2025032213A (ja) 2019-04-03 2024-12-05 対称性ジメチル化アルギニン分析物に対する抗体及びその用途

Country Status (6)

Country Link
US (9) US10745492B1 (enExample)
EP (1) EP3948280A4 (enExample)
JP (3) JP7368867B2 (enExample)
KR (2) KR102919306B1 (enExample)
GB (3) GB2612724B (enExample)
WO (1) WO2020204994A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3259593T3 (fi) * 2015-02-20 2023-01-13 Homogeeninen immunomääritys, jossa on taustasignaalikompensointi
US10745492B1 (en) 2019-04-03 2020-08-18 Ark Diagnostics, Inc. Antibodies to symmetrically dimethylated arginine analytes and use thereof
AU2023213987A1 (en) 2022-01-26 2024-09-05 Idexx Laboratories, Inc. Methods and compositions for differentiating progressive chronic kidney disease from stable chronic kidney disease
US12163955B2 (en) 2023-03-20 2024-12-10 Ark Diagnostics, Inc. Antibodies to methotrexate and uses thereof
WO2025205769A1 (ja) * 2024-03-26 2025-10-02 富士フイルム株式会社 α－アミラーゼと対称性ジメチルアルギニンとのコンジュゲート、およびその応用
KR102955018B1 (ko) * 2024-10-24 2026-04-21 중앙대학교 산학협력단 대칭 디메틸아르기닌 검출용 신규한 펩타이드 및 이를 이용한 생체물질 검출용 조성물

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4593089A (en) 1980-07-30 1986-06-03 Abbott Laboratories Fluorescent polarization immunoassay utilizing substituted triazinylaminofluorescein aminoglycosides
US4492762A (en) 1981-12-11 1985-01-08 Abbott Laboratories Fluorescent polarization immunoassays
US4668640A (en) 1981-12-11 1987-05-26 Abbott Laboratories Fluorescence polarization immunoassay utilizing substituted carboxyfluoresceins
US4435504A (en) 1982-07-15 1984-03-06 Syva Company Immunochromatographic assay with support having bound "MIP" and second enzyme
US4751190A (en) 1985-07-22 1988-06-14 Abbott Laboratories Fluorescence polarization immunoassay and reagents for use therein
US4959324A (en) 1989-03-16 1990-09-25 Chemtrak, Inc. Sample pad assay initiation device and method of making
US4847209A (en) 1987-11-09 1989-07-11 Miles Inc. Latex agglutination immunoassay in the presence of hemoglobin
US5340539A (en) 1989-03-16 1994-08-23 Chemtrak, Inc. Non-instrumented cholesterol assay
US5264180A (en) 1989-03-16 1993-11-23 Chemtrak, Inc. Mobile reagents in an analyte assay in a self-contained apparatus
US5416000A (en) 1989-03-16 1995-05-16 Chemtrak, Inc. Analyte immunoassay in self-contained apparatus
US5186844A (en) 1991-04-01 1993-02-16 Abaxis, Inc. Apparatus and method for continuous centrifugal blood cell separation
US5173193A (en) 1991-04-01 1992-12-22 Schembri Carol T Centrifugal rotor having flow partition
US5061381A (en) 1990-06-04 1991-10-29 Abaxis, Inc. Apparatus and method for separating cells from biological fluids
US5122284A (en) 1990-06-04 1992-06-16 Abaxis, Inc. Apparatus and method for optically analyzing biological fluids
MX9100717A (es) * 1990-08-24 1992-04-01 Syntex Inc Antagonistas de la bradiquinina
US5413732A (en) 1991-08-19 1995-05-09 Abaxis, Inc. Reagent compositions for analytical testing
DE4211351A1 (de) 1992-04-04 1993-10-07 Behringwerke Ag Verfahren zur Analyse partikelverstärkter Agglutinationsreaktionen auf Zentrifugalanalysatoren durch Bestimmung der Trübungsaufhellung
US6455288B1 (en) 1993-04-08 2002-09-24 Dade Behring Marburg Gmbh Homogeneous immunoassays using mutant glucose-6-phosphate dehydrogenases
US6235531B1 (en) 1993-09-01 2001-05-22 Abaxis, Inc. Modified siphons for improved metering precision
CA2205091A1 (en) 1994-12-23 1996-07-04 Zeneca Limited Chemical compounds
CA2244326C (en) 1997-08-11 2006-03-28 Shinichi Eda Microparticle enhanced light scattering agglutination assay and microparticle reagents therefor
IT1301992B1 (it) * 1998-08-04 2000-07-20 Menarini Ricerche Spa Peptidi ciclici ad attivita' antagonista specifica per il recettoreb2 della bradichinina e formulazioni che li contengono.
US6514770B1 (en) 1999-07-30 2003-02-04 Mitsubishi Chemical Corporation Immunoassay
JPWO2005075414A1 (ja) * 2004-02-04 2007-10-11 公立大学法人横浜市立大学 ペプチジルアルギニンデイミナーゼ４阻害剤
WO2006078813A2 (en) * 2005-01-21 2006-07-27 Biosite Incorporated Arginine analogs, and methods for their synthesis and use
HUE051130T2 (hu) * 2008-08-07 2021-03-01 Idexx Lab Inc Eljárások szimmetrikus dimetilarginin kimutatására
PL3041576T3 (pl) * 2013-09-05 2019-12-31 Idexx Laboratories, Inc. Sposoby wykrywania choroby nerek
US20160312208A1 (en) 2013-12-17 2016-10-27 Siemens Healthcare Diagnostics Inc. Preparation of multi-hapten mutant g6pdh conjugates and their use for detection of multiple analytes
FI3259593T3 (fi) 2015-02-20 2023-01-13 Homogeeninen immunomääritys, jossa on taustasignaalikompensointi
EP3761036B1 (en) 2015-03-03 2025-11-19 ARK Diagnostics, Inc. Pregabalin immunoassays
PL3289355T3 (pl) * 2015-04-30 2025-11-24 Idexx Laboratories, Inc. Sposoby wykrywania chorób nerek
CN111246918B (zh) * 2017-10-19 2024-06-14 艾德克斯实验室公司 对称二甲基精氨酸的检测
KR102818612B1 (ko) * 2019-02-14 2025-06-11 주식회사 바이오노트 대칭적 디메틸아르기닌과 특이적으로 결합하는 항체 및 이의 용도
US10745492B1 (en) 2019-04-03 2020-08-18 Ark Diagnostics, Inc. Antibodies to symmetrically dimethylated arginine analytes and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YOKORO, M., et al.，"Development of an Enzyme-Linked Immunosorbent Assay System for the Determination of Asymmetric Dimethylarginine Using a Specific Monoclonal Antibody."，BIOSCI. BIOTECHNOL. BIOCHEM.，2012年，Vol.76, No.2，pp.400-403，DOI: 10.1271/bbb.110727

Also Published As

Publication number Publication date
US11384158B2 (en) 2022-07-12
US11136412B2 (en) 2021-10-05
US20210139609A1 (en) 2021-05-13
GB202115215D0 (en) 2021-12-08
US20210024653A1 (en) 2021-01-28
KR102919306B1 (ko) 2026-01-27
GB2614970B (en) 2024-07-03
GB202300895D0 (en) 2023-03-08
US20200317818A1 (en) 2020-10-08
US11459403B2 (en) 2022-10-04
US20230151119A1 (en) 2023-05-18
GB202300894D0 (en) 2023-03-08
US20210206878A1 (en) 2021-07-08
JP2023056523A (ja) 2023-04-19
KR20230006059A (ko) 2023-01-10
KR20220002940A (ko) 2022-01-07
JP2022528465A (ja) 2022-06-10
GB2596993B (en) 2024-06-05
WO2020204994A1 (en) 2020-10-08
EP3948280A1 (en) 2022-02-09
JP2025032213A (ja) 2025-03-11
US11149093B2 (en) 2021-10-19
US10717787B1 (en) 2020-07-21
US20260109785A1 (en) 2026-04-23
EP3948280A4 (en) 2022-12-28
US10919982B2 (en) 2021-02-16
GB2612724A (en) 2023-05-10
US10745492B1 (en) 2020-08-18
GB2612724B (en) 2024-06-05
US20210403603A1 (en) 2021-12-30
GB2596993A (en) 2022-01-12
GB2614970A (en) 2023-07-26
KR102644096B1 (ko) 2024-03-06
US12391767B2 (en) 2025-08-19

Similar Documents

Publication Publication Date Title
US12391767B2 (en) Antibodies to symmetrically dimethylated arginine analytes and use thereof
US20220221446A1 (en) Methods for Detecting Symmetrical Dimethylarginine
US11703514B2 (en) Pregabalin immunoassays
JP2021156896A (ja) バックグラウンドシグナルを補正するホモジニアスなイムノアッセイ
AU2016254226B2 (en) Methods for detecting renal disease
US12163955B2 (en) Antibodies to methotrexate and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221007

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221222

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20221222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230706

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230905

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231005

R150 Certificate of patent or registration of utility model

Ref document number: 7368867

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150